Pre-made Magrolimab benchmark antibody ( Whole mAb, anti-CD47 therapeutic antibody, Anti-IAP/OA3/MER6 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-333
Pre-Made Magrolimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
---|---|---|---|---|
GMP-Bios-ab-333-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size: 1mg | 10mg | 100mg
Description
Products Name (INN Index) | Pre-Made Magrolimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody |
INN Name | Magrolimab |
Target | CD47 |
Format | Whole mAb |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | IgG4 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-III |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | 5iwl:AA:BB |
95-98% SI Structure | None |
Year Proposed | 2018 |
Year Recommended | 2019 |
Companies | Forty Seven;Merck KGaA;Stanford University |
Conditions Approved | na |
Conditions Active | Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer |
Conditions Discontinued | Lymphoma |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<